Vestal Point Capital
Latest statistics and disclosures from Vestal Point Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ASND, ACLX, NUVL, ABVX, ALC, and represent 21.85% of Vestal Point Capital's stock portfolio.
- Added to shares of these 10 stocks: ABVX (+$85M), ASND (+$80M), BDX (+$56M), RGEN (+$54M), DXCM (+$44M), GMED (+$43M), ALC (+$43M), BIIB (+$39M), IONS (+$38M), RAPP (+$28M).
- Started 24 new stock positions in APGE, PASG, NVCR, BLTE, AXSM, DXCM, INSP, CGON, BIIB, REGN. BHVN, ABVX, KOD, GLUE, ESTA, MYGN, AGIO, TVRD, LUNG, RGEN, GSK, RARE, RCUS, RAPP.
- Reduced shares in these 10 stocks: QURE (-$203M), CYTK (-$124M), ACLX (-$123M), JAZZ (-$92M), DNTH (-$80M), VERA (-$68M), GEHC (-$52M), KALV (-$48M), XENE (-$36M), EXAS (-$34M).
- Sold out of its positions in ATRA, COGT, COO, EW, GEHC, MLTX, NBIX, Passage Bio, GPCR, TMO. TVTX, VRDN, ZBH, MDT, PRGO.
- Vestal Point Capital was a net seller of stock by $-330M.
- Vestal Point Capital has $2.2B in assets under management (AUM), dropping by 16.59%.
- Central Index Key (CIK): 0001974915
Tip: Access up to 7 years of quarterly data
Positions held by Vestal Point Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Vestal Point Capital
Vestal Point Capital holds 81 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ascendis Pharma A/S Sponsored Adr (ASND) | 5.4 | $119M | +200% | 600k | 198.81 |
|
| Arcellx Common Stock (ACLX) | 4.6 | $103M | -54% | 1.3M | 82.10 |
|
| Nuvalent Inc-a (NUVL) | 4.3 | $95M | +2% | 1.1M | 86.48 |
|
| Abivax SA Sponsored Ads (ABVX) | 3.8 | $85M | NEW | 1.0M | 84.90 |
|
| Alcon Ord Shs (ALC) | 3.7 | $82M | +109% | 1.1M | 74.51 |
|
| Bicara Therapeutics (BCAX) | 3.6 | $81M | +2% | 5.1M | 15.79 |
|
| Amicus Therapeutics (FOLD) | 3.5 | $77M | -18% | 9.8M | 7.88 |
|
| Globus Medical Cl A (GMED) | 3.2 | $72M | +150% | 1.3M | 57.27 |
|
| Ionis Pharmaceuticals (IONS) | 3.2 | $70M | +115% | 1.1M | 65.42 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 3.0 | $66M | -58% | 500k | 131.80 |
|
| Becton, Dickinson and (BDX) | 2.7 | $61M | +1200% | 325k | 187.17 |
|
| Scholar Rock Hldg Corp (SRRK) | 2.5 | $56M | 1.5M | 37.24 |
|
|
| Immatics NV SHS (IMTX) | 2.4 | $54M | 6.4M | 8.52 |
|
|
| Repligen Corporation (RGEN) | 2.4 | $54M | NEW | 400k | 133.67 |
|
| Dianthus Therapeutics (DNTH) | 2.1 | $46M | -63% | 1.2M | 39.35 |
|
| BioMarin Pharmaceutical (BMRN) | 2.0 | $45M | +66% | 830k | 54.16 |
|
| Xenon Pharmaceuticals (XENE) | 2.0 | $44M | -45% | 1.1M | 40.15 |
|
| Dex (DXCM) | 2.0 | $44M | NEW | 650k | 67.29 |
|
| Cytokinetics Com New (CYTK) | 1.8 | $40M | -75% | 725k | 54.96 |
|
| Biogen Idec (BIIB) | 1.7 | $39M | NEW | 275k | 140.08 |
|
| Cidara Therapeutics Com New (CDTX) | 1.7 | $38M | -20% | 400k | 95.76 |
|
| Astria Therapeutics (ATXS) | 1.6 | $36M | +9% | 5.0M | 7.28 |
|
| Dyne Therapeutics (DYN) | 1.6 | $35M | +281% | 2.8M | 12.65 |
|
| Tyra Biosciences (TYRA) | 1.5 | $34M | -8% | 2.4M | 13.99 |
|
| Abbott Laboratories (ABT) | 1.5 | $34M | +42% | 250k | 133.94 |
|
| Disc Medicine (IRON) | 1.5 | $33M | +257% | 500k | 66.08 |
|
| Nurix Therapeutics (NRIX) | 1.4 | $32M | +73% | 3.5M | 9.24 |
|
| Crinetics Pharmaceuticals In (CRNX) | 1.4 | $31M | -50% | 750k | 41.65 |
|
| Celldex Therapeutics Com New (CLDX) | 1.4 | $31M | -31% | 1.2M | 25.87 |
|
| Zymeworks Del (ZYME) | 1.4 | $30M | +53% | 1.8M | 17.08 |
|
| Danaher Corporation (DHR) | 1.3 | $30M | +200% | 150k | 198.26 |
|
| Revolution Medicines (RVMD) | 1.3 | $29M | -47% | 630k | 46.70 |
|
| Rapport Therapeutics (RAPP) | 1.3 | $28M | NEW | 950k | 29.70 |
|
| Enliven Therapeutics (ELVN) | 1.1 | $24M | +364% | 1.2M | 20.47 |
|
| Geron Corporation (GERN) | 1.1 | $24M | -27% | 17M | 1.37 |
|
| Belite Bio Sponsored Ads (BLTE) | 1.0 | $23M | NEW | 313k | 74.00 |
|
| Ultragenyx Pharmaceutical (RARE) | 1.0 | $23M | NEW | 750k | 30.08 |
|
| Vera Therapeutics Cl A (VERA) | 1.0 | $22M | -75% | 760k | 29.06 |
|
| Lexeo Therapeutics (LXEO) | 1.0 | $22M | 3.3M | 6.64 |
|
|
| Black Diamond Therapeutics (BDTX) | 0.9 | $21M | 5.6M | 3.79 |
|
|
| Day One Biopharmaceuticals I (DAWN) | 0.9 | $19M | -10% | 2.7M | 7.05 |
|
| Solid Biosciences Com New (SLDB) | 0.8 | $18M | +97% | 3.0M | 6.17 |
|
| Axsome Therapeutics (AXSM) | 0.8 | $18M | NEW | 150k | 121.45 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.8 | $18M | +83% | 5.5M | 3.27 |
|
| Apogee Therapeutics (APGE) | 0.8 | $17M | NEW | 425k | 39.73 |
|
| Savara (SVRA) | 0.6 | $14M | -63% | 4.0M | 3.57 |
|
| Bruker Corporation (BRKR) | 0.6 | $14M | -12% | 440k | 32.49 |
|
| Regeneron Pharmaceuticals (REGN) | 0.6 | $14M | NEW | 25k | 562.27 |
|
| uniQure NV SHS (QURE) | 0.6 | $13M | -93% | 225k | 58.37 |
|
| Beta Bionics (BBNX) | 0.5 | $12M | +9% | 600k | 19.87 |
|
| Biohaven Put Option (BHVN) | 0.5 | $11M | NEW | 702k | 15.01 |
|
| Inspire Med Sys (INSP) | 0.5 | $10M | NEW | 135k | 74.20 |
|
| Kalvista Pharmaceuticals (KALV) | 0.4 | $9.1M | -83% | 750k | 12.18 |
|
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 0.4 | $8.7M | +240% | 170k | 51.29 |
|
| Applied Therapeutics (APLT) | 0.4 | $8.6M | +23% | 14M | 0.60 |
|
| Cg Oncology (CGON) | 0.3 | $7.0M | NEW | 175k | 40.28 |
|
| Voyager Therapeutics (VYGR) | 0.3 | $6.9M | 1.5M | 4.67 |
|
|
| Tvardi Therapeutics (TVRD) | 0.3 | $6.5M | NEW | 167k | 38.97 |
|
| Ventyx Biosciences (VTYX) | 0.3 | $6.4M | +2% | 2.1M | 3.11 |
|
| Monte Rosa Therapeutics (GLUE) | 0.3 | $5.9M | NEW | 800k | 7.41 |
|
| GSK Sponsored Adr (GSK) | 0.2 | $5.4M | NEW | 125k | 43.16 |
|
| Novocure Ord Shs (NVCR) | 0.2 | $5.2M | NEW | 400k | 12.92 |
|
| Agios Pharmaceuticals (AGIO) | 0.2 | $5.1M | NEW | 127k | 40.14 |
|
| Nyxoah SA SHS (NYXH) | 0.2 | $5.1M | -21% | 1.1M | 4.60 |
|
| Myriad Genetics (MYGN) | 0.2 | $4.3M | NEW | 600k | 7.23 |
|
| EXACT Sciences Corporation (EXAS) | 0.2 | $4.1M | -89% | 75k | 54.71 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.2 | $4.1M | NEW | 100k | 40.99 |
|
| Kodiak Sciences (KOD) | 0.2 | $4.1M | NEW | 250k | 16.37 |
|
| Alto Neuroscience Com Shs (ANRO) | 0.2 | $3.8M | 950k | 4.02 |
|
|
| Arcutis Biotherapeutics (ARQT) | 0.2 | $3.8M | +110% | 200k | 18.85 |
|
| Arcus Biosciences Incorporated (RCUS) | 0.2 | $3.4M | NEW | 250k | 13.60 |
|
| Fate Therapeutics (FATE) | 0.1 | $3.2M | 2.5M | 1.26 |
|
|
| Alector (ALEC) | 0.1 | $2.9M | 980k | 2.96 |
|
|
| Engene Holdings (ENGN) | 0.1 | $2.5M | 370k | 6.83 |
|
|
| Passage Bio Com New (PASG) | 0.1 | $2.4M | NEW | 305k | 8.03 |
|
| Sutro Biopharma (STRO) | 0.1 | $2.3M | 2.6M | 0.87 |
|
|
| OnKure Therapeutics Com Cl A (OKUR) | 0.1 | $1.7M | 635k | 2.75 |
|
|
| Pulmonx Corp (LUNG) | 0.1 | $1.3M | NEW | 830k | 1.62 |
|
| Macrogenics (MGNX) | 0.0 | $470k | 280k | 1.68 |
|
|
| Tenax Therapeutics Com New (TENX) | 0.0 | $407k | 53k | 7.61 |
|
|
| Traws Pharma Com New (TRAW) | 0.0 | $278k | 150k | 1.85 |
|
Past Filings by Vestal Point Capital
SEC 13F filings are viewable for Vestal Point Capital going back to 2024
- Vestal Point Capital 2025 Q3 filed Nov. 14, 2025
- Vestal Point Capital 2025 Q2 filed Aug. 14, 2025
- Vestal Point Capital 2025 Q1 filed May 15, 2025
- Vestal Point Capital 2024 Q4 filed Feb. 14, 2025
- Vestal Point Capital 2024 Q3 filed Nov. 14, 2024
- Vestal Point Capital 2024 Q2 filed Aug. 14, 2024